Quintiles Library

Precision Enrollment
Featured Video

Quintiles Precision Enrollment
Show Filters
Press Release
RESEARCH TRIANGLE PARK, N.C. – May 31, 2016 – Quintiles, the world’s largest provider of product development and integrated healthcare services, today announced its Precision Enrollment offering. The new enrollment model is designed to significantly accelerate site start-up and patient recruitment in oncology clinical trials working with the company’s network of investigative sites across the U.S and leveraging secondary data (e.g. electronic health records-EHRs.) In this new model, the traditional site start-up pathway is realigned so a site is only opened after a patient is identified.  “The rise of precision medicine, scarcity of patients and investigators, combined with increasingly complex trial protocols, requires innovative approaches to clinical trial implementation,” said...
Read More
Infographic
Developing cancer treatments requires the right strategic approach to manage risks and make critical go/no-go decisions. Partner with Quintiles for the global scientific, clinical and technological resources needed for successful oncology drug...
Read More
White Paper
As we enter a new era of value and outcomes-based healthcare, exercising “systems thinking” – accounting for political, economic, social and technological factors – will be critical to our collective success in improving population health. Now more than ever, industry players must team up with other healthcare stakeholders if they want to improve system performance and optimize patient outcomes. Biopharma companies who do will be amply rewarded for their innovation and contribution to healthcare system value and...
Explore More
Article
Payers, providers, patients and pharmaceutical companies all want to understand the value of specific treatments - and patient registries can help them do that. These online data platforms give patients and providers a single place to record information about diagnosis, condition and treatment...
Explore More
White Paper
As new immunotherapies continue to be developed, assumptions regarding patterns of clinical responses based on responses to chemotherapy are no longer tenable: appropriate clinical trial methodology must be employed since their novel mechanisms of action lead to novel patterns of clinical response.  Employment in clinical trials of imaging techniques and criteria can be of considerable help in this regard, as discussed in this White...
Explore More
White Paper
“The Art & Science of Evidence – Oncology” is one in a series of compendiums featuring blogs and bylined articles from Quintiles’ experts. This collection explores innovative accomplishments, new opportunities and ongoing challenges in oncology and immunotherapy research for the coming years. This future state of maximally leveraging genomic information allows for truly personalized precision cancer care. In short, genomics-based techniques will greatly influence the oncology ecosystem from the very beginning of drug discovery through...
Explore More
Brochure
With the list of rare diseases across the globe expanding to nearly 7,000, it is critical to make new treatments available for these uncommon conditions. While regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and  predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly payers are making hard choices about reimbursing these therapies. As a result, there are gaps in knowledge, a lack of standards and delays in patient diagnosis. Real-world evidence can play a huge role in expediting the development and commercialization of orphan medical products. With Quintiles as your strategic partner,...
Read More
Presentation
Since the introduction of the 2010 European Pharmacovigilance legislation, a broad spectrum of public available data on Post Authorisation Safety Studies (PASS) have emerged including information on study regulatory, methodological and operational considerations. Please join us in a complimentary webinar that aims to review scientific and practical insights on PASS landscape during the first three complete years of the legislation and to provide the latest perspectives in observational post-marketing studies.  This webinar will be presented by Priscilla Velentgas, Senior Director, Epidemiology at Quintiles Real World & Late Phase Research, and Pierre Engel, PharmD, MPH, PhD, Director of Epidemiology at Quintiles Real World & Late Phase Research and member of the Steering Group of the...
Explore More
Fact Sheet
With the Quintiles Regulatory and Safety Optimization Solution, you partner with our experts to assess the value, strategy and key activities required to integrate regulatory, safety and benefit-risk management (BRM) capabilities. We analyze key data and information related to established products and current regulatory and safety operations. Our regulatory and safety experts perform a detailed diagnostic, including assessments of portfolio, operational capabilities and financial impact, to develop a solution. We create a roadmap to align your strategy, based on product, functional and regional priorities, then help you achieve it – to reduce complexity, improve compliance and minimize...
Read More
Article
Until relatively recently, the number often quoted as the cost of bringing a new drug to market was $1 billion. In November 2014, the Tufts Center for the Study of Drug Development reported that developing new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 billion. Recent analysis shows that not only have costs risen, but there is a high variability among companies in their “costs-per-successful-product” reaching the...
Explore More
Video
Where expert teams collaborate to create custom technology solutions that tackle some of healthcare's biggest...
Video
At Quintiles, our employees who have nursing experience play a vital role in helping to improve patient outcomes. Five Quintiles leaders speak about how their nursing backgrounds help bring people and knowledge together for a healthier...
Video
At Quintiles, we have hundreds of employees with nursing experience. As part of International Nurses Day, we celebrate those who play a vital role in bringing people and knowledge together for healthier world....
Video
Take a moment to watch this animated video, and you will get an engaging sense of how Quintiles' Precision Enrollment can help reduce your study start up by opening sites to studies only when they have a qualified patient. The right sites. The right patients. Within 21...
Article
According to Global Genes, more than 350 million people worldwide suffer from rare diseases. Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment. Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 230 rare disease studies since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to...
Explore More
Fact Sheet
Clinical trial designs are becoming more complex, and there are increasing demands on clinical supply managers to move new therapies through the supply chain more efficiently and cost-effectively. A seamless and integrated supply chain strategy is critical to helping ensure that the patient receives the right treatment at the right time. Learn how you can execute your trials with confidence and efficiency with our integrated supply chain management...
Read More
Press Release
All-stock transaction with combined 2015 revenue of $7.2 billion and combined equity market capitalization of $17.6 billion Broad range of healthcare information, technology and services solutions to drive efficiencies and insights across the entire life sciences product lifecycle, from R&D through commercial execution to real-world patient outcomes. Capabilities to address mission-critical healthcare operations with a market opportunity of more than $230 billion. Quintiles IMS will: Accelerate patient access to innovative medicines by increasing the productivity of the $100 billion spent on drug development Demonstrate the value and effectiveness of medicines as part of the $80 billion opportunity for Real-World Evidence (RWE) services and...
Read More
Press Release
Agreement to merge with IMS Health in all-stock transaction to create Quintiles IMS, an industry-leading information and technology-enabled healthcare services provider 8.4% constant currency service revenue growth compared to the first quarter of 2015 $0.89 diluted adjusted EPS representing 23.6% growth compared to the first quarter of 2015 Net new business of $1.03 billion in the first quarter of 2016, representing a 0.93 book-to-bill and resulting in backlog of $12 billion as of March 31, 2016 Cash flow from operations of $112.1 million and free cash flow of $85.9 million in the three months ended March 31, 2016 Reaffirming full year 2016 service revenue constant currency growth guidance of 7.0% to 8.5% compared to full year 2015 and diluted adjusted EPS...
Read More
Fact Sheet
Healthcare systems are transforming from volume to value to outcomes. This shift fundamentally changes the way that biopharmaceutical companies approach drug development. The Quintiles Value & Outcomes Strategy Solution helps clients develop the evidence base to define the clinical, economic and humanistic profile of products. These are tailored to stakeholders’ needs to help improve their probability of success and healthcare system...
Read More
White Paper
Biopharma companies face significant complexity working in a global environment governed by rigorous regulatory and safety requirements that vary by market. To effectively manage your portfolio, you need to do more than simply meet regulatory requirements. By aligning all aspects of marketed product maintenance, including regulatory, safety and benefit-risk management, you can improve compliance, and reduce complexity and...
Explore More